Learn about cost, uses, and more of Keytruda ... It’s available only as a brand-name drug. Keytruda isn’t available in a biosimilar form. Biosimilars are like generic drugs.

Keytruda (pembrolizumab) is a brand-name IV infusion prescribed to treat many types of cancer, including melanoma and lung cancer. As with other drugs, Keytruda can cause side effects, such as eye ...

Opdivo (nivolumab) and Keytruda (pembrolizumab) are brand-name biologic drugs prescribed for several types of cancer. They are given by a healthcare professional as an intravenous (IV) infusion.

Keytruda comes only as a brand-name drug. There are no biosimilar forms available. Biosimilars are like generic drugs. Unlike generics, which are made for nonbiologic drugs, ...

Merck's Phase 1 study of 495 patients with NSCLC, the most common form of the disease, found that 45 percent of patients with high levels of PD-L1 responded to Keytruda, compared with 16.5 percent ...

A decade later, this brand has entered 53 countries, is reimbursed in 68% of these markets, and has entered a new market at nearly the same rate as Keytruda, 64.5 days on average.

The U.S. Food and Drug Administration (FDA) has approved a new treatment option for patients with advanced esophageal cancer — the immunotherapy drug pembrolizumab, known by its brand name ...

Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab, sold under brand name Keytruda, in a Phase 3 trial involving lung-cancer patients. Merck shares, which were up ...